Work

Real-World Effectiveness and Safety of Pre-mix 70/30 Insulin Initiation in Poorly Controlled Type 2 Diabetes: a Multicentre Pakistani Cohort

Year: 2026
Type: article
Abstract: INTRODUCTION: In lower- and middle-income countries, insulin choice at initiation is driven as much by cost as by clinical need. Low-cost human pre-mix 70/30 insulin predominates in Pakistan, yet prospective real-world evidence on its outcomes and true cost is scarce. METHODS: In this investigator-initiated, single-arm, prospective observational study at 12 sites in Pakistan, insulin-naïve adults with type 2 diabetes and HbA1c 9% or higher despite two or more oral drugs were started on human pre-mix 70/30 insulin at physician discretion and followed for 6 months, with assessments at baseline, day 90 and day 180. The primary outcomes were change in HbA1c and incidence of hypoglycaemia (classified by American Diabetes Association levels). A descriptive cost-consequence analysis (patient out-of-pocket perspective) was a pre-specified secondary exploratory objective. RESULTS: A total of 384 of 430 screened patients were enrolled, with a mean baseline HbA1c of 11.2 ± 1.5%. HbA1c fell to 9.3 ± 1.5% at day 90 and to 8.8 ± 1.5% at day 180, a mean reduction of 2.3 ± 1.8% (p < 0.001), with no significant change in body weight. By day 180, 242 of 310 patients (78.1%) had achieved at least a 1% reduction in HbA1c, and 28 patients (9.0%) reached below 7%. Confirmed hypoglycaemia below 70 mg/dL occurred in eight patients (2.1%), and no severe or treatment-limiting events were recorded. Mean 6-month direct medical cost was 36,269 Pakistani Rupee (PKR) per patient. Insulin acquisition accounted for just PKR 7200 of this (19.8%), while consultations, injection consumables, diagnostics and self-monitoring made up the remainder. CONCLUSIONS: In routine practice, human pre-mix 70/30 insulin produced clinically meaningful and sustained HbA1c reductions with a favourable safety profile, supporting its effectiveness for insulin initiation in poorly controlled type 2 diabetes. Affordability, however, was governed by the total cost of care rather than insulin price alone.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $7,400
OpenAlex ID: W7236405250
FWCI:
Cites: 28
Cited by:
Related to: 10